become refractory to androgens within a few years. The molecular changes underlying androgen-independence and tumour progression are as yet widely unknown.
Unlike the oestrogen and progesterone receptor status in breast cancer, the expression of the AR molecule in PC does not correlate with clinical response to ADT (Miyamoto et al, 1993; Trapman and Brinkmann, 1996) . This finding can be explained partly by mutations (Klocker et al, 1994; Peterziel et al, 1995; Taplin et al, 1995; Suzuki et al, 1996) or amplifications of the AR gene after ADT ( V isakorpi et al, 1995) . Howeve r, these aberrations are not present uniformly in hormone-independent carcinomas. Consequentl y, other mechanisms must be involved in the evolution of androgen-independent tumour progression as well.
In analogy to the physiological situation, the analysis of factors regulating cell proliferation and apoptosis may be important in this context, not only for scientific reasons, but also from a clinical point of vie w . To the best of our knowledge, howeve r, studies have been missing up to now that investigate changes of proliferationand programmed cell death (PCD)-associated factors in PC after ADT over a longer period of time. In order to avoid a therapyrelated bias, the cases were classified into groups with either conventional ADT (by orchiectomy and/or drugs) or ADT and additional therapy regimens (radiation or chemotherapy). The proliferation-associated Ki-67 antigen, the p53 protein and its physiologic effector, the p21/WAF1 protein, both known to be involved in the regulation of cell cycle and PCD/apoptosis, the apoptosis-inhibiting bcl2-oncoprotein, and the AR molecule were determined immunohistochemically. Furthermore, the PCD rate was visualized in situ by enzymatic detection of DNA fragmentation and quantified. The prognostic impact of these parameters was tested before and after long-standing ADT.
MATERIALS AND METHODS

Materials and patients
Formalin-fixed and paraffin-embedded tumour tissue from a total of 69 patients with locally advanced or metastasized primary prostatic carcinomas was studied after ADT with and without additional therapy regimens. The mean duration of ADT was 40.6 months ± 39.3 (median 30 months; range 0.4-169.4 months). The mean age of the patients at time of diagnosis was 67.5 ± 8.8 years (range 46-83 years).
Tumours were graded according to Gleason and Mellinger (Gleason, 1966; Gleason and Mellinger, 1974) . For statistical calculations, a grade compression was performed with a cut-point between scores 6 and 7, i.e. low-grade vs high-grade (Gleason, 1992 ; Table 1 ). In 42 cases, paired specimens from both the untreated primary tumour and the recurrence after ADT were available (mean duration of ADT 26.8 ± 29.1 months; median 16.5 months, range 0.4-105.8 months; Table 2 ).
In 26 of these cases, only a conventional ADT was performed ('core-group') either by orchiectomy (OE; n = 8), or by OE and drugs (n = 11) or only by drugs (n = 7). For the ADT by drugs flutamide, fosfestrol, or cyproteronacetate were used primarily; later the patients were also treated with leuprorelinacetate, buserelinacetate, or goserelinacetate.
In the remaining 16 cases, an additional radiation (n = 2) or chemotherapy (n = 9), or a form of therapy that was not thoroughly documented (n = 5), was applicated in the further course. These cases were studied separately in order to avoid a therapy-related bias. For chemotherapy estramustin, 4′-epirubicin, or cisplatin were used.
In addition, tumour tissue from 27 patients after ADT was studied without paired material from the primary tumour. Fourteen of these patients were pretreated only by conventional ADT (OE: n = 4; OE + drugs: n = 7; only drugs: n = 3). Thus, tumour tissue from a total of 40 patients after conventional ADT alone was available. In the remaining 13 cases, an additional radiation (n = 3), chemotherapy (n = 8), or therapy not further specified (n = 2) had been performed. Gleason scores and material (if not mentioned: transurethral resection/TUR; a transrectal punch biopsy, b subtotal transabdominal resection, c pulmonary metastasis) of the prostatic carcinomas after ADT discriminated according to subsequent therapy; all tumours under study (n = 69; median 9, mean 8.97 ± 1.3) and cases pretreated only by conventional androgen deprivation (castration and/or drugs; n = 40; median 9, mean 8.8 ± 1.5). For statistical calculations a grade compression was performed with a cut-point between scores 6 and 7 (low-grade vs high-grade). Gleason scores and material (if not mentioned = transurethral resection/TUR; a transrectal punch biopsy, b subtotal transabdominal resection) of the untreated primary prostatic carcinomas discriminated by subsequent therapy; all tumours under study (n = 42; median 7, mean 7.3 ± 1.5) and cases treated only by conventional ADT in the further course (castration and/or drugs; n = 26; median 7, mean 7.0 ± 1.3). For statistical calculations a grade compression was performed with a cutpoint between scores 6 and 7 (low-grade vs high-grade).
The material comprised 83 transurethral resections (TUR), 22 transrectal punch biopsies, four subtotal transabdominal prostatic resections, and two pulmonary metastasis (Tables 1 and 2 ). All samples were routinely fixed in 4% buffered formalin and embedded in paraffin (total of 111 paraffin blocks).
In the tumour tissue after ADT nuclear size reduction, loss of recognizable nucleoli, chromatin condensation, nuclear pyknosis and vacuolization of the cytoplasm of the tumour cells were recorded as histopathological signs of regression (Civantos et al, 1995) . If these features were lacking, the case was classified histopathologically as regression-negative.
In 66 cases, clinical follow-up data were available, including all patients with paired tumour samples before and after ADT (mean time of observation: 59.5 ± 48.9 months; median 47 months; range: 1-215 months). Twenty-seven of 66 patients died.
Methods
Immunohistochemistry
Sections (3-4 µm thick) were cut from the paraffin blocks and mounted on Super-Frost/Plus microscope slides (Menzel, Germany) and dried for 24 h at 56°C. After deparaffinization, rehydration and washing in phosphate-buffered saline (PBS) the slides were placed in a Coplin jar that was filled with 10 mM citrate buffer (pH 6.0). The jar was heated in an autoclave (Webeco, Germany) at 120°C (1.2 bar) for 20 min (Piffko et al, 1995) . The jar was then allowed to cool at room temperature. After three washings in PBS the slides were incubated with 75 µl of the primary monoclonal antibodies prediluted in 1% bovine serum albumin (Sigma, Deisenhofen, Germany) in PBS for 20 h at 6°C in a wet chamber (Table 3) .
The reactions were visualized by an amplified biotin-streptavidin method (Super Sensitive Multilink Immunodetection System TM ; BioGenex, San Ramon, CA, USA). For this purpose, after washing in PBS, the sections were incubated for 30 min (21°C, wet chamber) with the biotinylated anti-mouse antibody (Super Sensitiv Multilink, HK 340-9K; BioGenex, USA). After washing again in PBS an incubation with alkaline-phosphatase conjugated streptavidin (Super Sensitiv Label, HK 331-9K; BioGenex, USA) was performed (30 min, 21°C, wet chamber). Fast red-naphthole AS-MX phosphate (F-4523; Sigma, Germany) served as chromogene. Finally, the slides were counterstained with haematoxylin and mounted in Aquatex (Merck, Germany).
Analysis of the immunohistochemical reactions
Ki-67
According to the immunoreaction in 1000 tumour cells/tumour the mean percentage of nuclei with a positive immunoreaction was determined (= Ki-67 index). A Ki-67 index was classified as high if it was ≥ 14.7%, which represented the median value in the 42 primary PC before ADT.
AR
A tumour was classified as positive for AR molecule expression if a clear positive nuclear reaction was present in > 95% of the tumour cells. Cases with no, or only single, positive cells (< 5%) were regarded as negative.
p53 and p21/WAF
The results of the p53 and p21/WAF1 immunoreaction were recorded as positive if a distinct nuclear staining was seen in at least 20% of the tumour cells in a microscope field at 100-fold magnification (Zeiss Axioskop microscope: objective 10/0.30, ocular 10×/20; Zeiss, Germany). A further subclassification was performed in cases with p21/WAF1 immunoreactivity in > 50% of all tumour cells; those cases were classified as high-rate positive. Cases with no, or only single, positive cells were regarded as negative.
This classification was used because there is increasing evidence that p53 immunoreactivity in only a few tumour cells, or even normal cells, does not correlate with a TP53 mutation, but represents overexpression of wild-type p53 due to physiologic DNA repair. Accordingly, the effector of the wild-type p53-protein, i.e. p21/WAF1, can physiologically show a positive reaction in single cells.
bcl-2
The immunohistochemical results for bcl-2 were recorded as positive if the tumour cells showed an unequivocally strong cytoplasmatic immunoreaction in at least 20% of the tumour cells in a microscope field at 100-fold magnification (see above). Cases with only equivocally faint staining were regarded as negative. Positive-reacting lymphocytes and basal cells in preserved nonneoplastic prostatic glands served as internal control.
Detection of apoptotic cells in paraffin sections
DNA fragments of apoptotic cells were visualized by an enzymatic reaction (Gavrieli et al, 1992; Ansari et al, 1993) . After dewaxing in xylene, rehydration, washing in PBS and pretreatment of the sections with proteinase K (Sigma, Germany; 40 µg ml -1 in PBS, 21°C, 45 min), the endogenous peroxidase activity was blocked in 3% hydrogen peroxide for 5 min. Subsequently, the terminal transferase reaction was performed using the ApopTag TM kit (In Situ Apoptosis Detection Kit, Peroxidase, S 7100-Kit; ONCOR, Gaithersburg, MD, USA). DAB (3,3'-diaminobenzidintetrahydrochloride; D-51905; Sigma, Germany) served as chromogen (one tablet in 15 ml PBS). After 5 min of incubation with DAB, Primary monoclonal antibodies used for the immunohistochemical reactions and dilutions (*in 1% bovine serum albumin (Sigma, Germany) in PBS).
the slides were washed in running tap water for 10 min and in double-distilled water (DDW) for 5 min. Afterwards, the slides were counterstained with methyl green (HK 141-7K; BioGenex, USA) for 10 min under a cover-glass at 21°C, washed again in DDW and mounted with Aquatex (Merck, Germany). As positive controls, preserved non-neoplastic prostatic glands within the slides from primary tumours, or lymphocytes in lymph follicles, were used. Since the enzymatic reaction described labels, both apoptotic cells and areas of necrosis, the only labelled cells that were regarded as positive were those that showed additional characteristics of apoptosis, e.g. isolated localization within an intact cell complex without an inflammatory reaction. At least 10 000 tumour cells per case were evaluated. The results were expressed as positive cells per 1000 tumour cells.
As 2.5% represented the median value of apoptotic cells in the 42 primary tumours before ADT, a PCD index < 2.5% was considered low, and a PCD index > 2.5% high.
Statistical analyses
Mean parameter values ± standard error of the mean (S.E.M.) were statistically compared by Spearman correlation, χ 2 analysis, Fisher's exact test, Wilcoxon's signed rank test, and the McNemar test (Hollander and Wolfe, 1973; Breslow and Day, 1980) . Survival analyses were performed by Kaplan-Meier curves and the log-rank test using the SPSS statistical software (SPSS Inc., Chicago, IL, USA). P < 0.05 was regarded as statistically significant.
RESULTS
Prostatic carcinomas before ADT
AR molecule
All primary PC showed a nuclear expression of the AR molecule before ADT.
bcl-2
Twenty of 42 PC before ADT (48%) exhibited a positive cytoplasmatic immunohistochemical reaction for bcl-2. In the subgroup of 26 carcinomas treated later only by conventional ADT, 15 cases were bcl-2-positive (58%). The pattern of immunostaining was not uniform within the tumours; clusters of cells that reacted positively alternated with only faint staining areas within an individual carcinoma without correlation to histologic grade of the tumours or the other parameters under study. A positive cytoplasmatic bcl-2 reaction was also present in the basal cells in nonneoplastic glands in the adjacent prostate tissue corresponding with the physiologic proliferative zone and in reactive lymphocytes/lymphoid follicles infiltrating the prostate.
p53
Eleven of 42 untreated carcinomas (26%) were immunohistochemically p53-positive (including six of the 26 cases (23%) with subsequent conventional ADT without additional radiation or chemotherapy), whereas in the remaining tumours no nuclear p53 accumulation could be observed. In all positive carcinomas, however, parts of the neoplasms remained negative. All p53-positive carcinomas were histologically high-grade tumours; however, the correlation between p53 and histological grade was not statistically significant. Furthermore, no correlations between p53 accumulation and the other parameters under study could be found. The preserved non-neoplastic prostatic tissue showed no p53 immunoreactivity.
p21/WAF1
Seven of 42 PC before ADT (17%) showed a positive nuclear immunoreaction for p21/WAF1. In this group, p21/WAF1 expression was correlated positively with Ki-67 index (P < 0.01, Fisher's exact test). In the subgroup of 26 patients with conventional ADT in the later course, four tumors were p21/WAF1-positive (15%). The reaction pattern was heterogeneous in the tumours demonstrating positive foci of tumour cells alternating with negative areas (Figure 1 ). The distribution of cases with focal and high-rate p21/WAF1 immunoreactivity is shown in Table 4 . No statistically significant correlations could be established between p21/WAF1 immunoreactivity, histologic tumour grade or other parameters under study. p21/WAF1-positive tumours were histologically mostly high-grade carcinomas, showed high Ki-67 and PCD index, and were bcl-2-positive; however, these associations were statistically not significant. In the non-neoplastic prostate tissue, very few epithelial cells showed an occasional positive p21/WAF1 immunoreactivity (< 1%) in all cases. 
Ki-67
The mean value of the Ki-67 index was 17.4 ± 12.1% in the untreated PC. According to the defined classes of proliferation, the cases with low and high Ki-67 were distributed equally (50%). In the core group, 62% of the cases (n = 16) showed a low, and 38% (n = 10) a high, Ki-67 index respectively. Statistically significant positive correlations could be established between Ki-67 index and histologic grade (P < 0.0001, Spearman correlation) as well as between Ki-67 index and PCD index (P < 0.05, Spearman correlation).
poptosis
In the 42 tumours before ADT, the mean PCD index was 2.96 ± 2.6%. The PCD index was graded as low (< 2.5%) in 22 cases (52%) and as high in 20 carcinomas (48%; Figure 2) . From the 26 prostate cancer patients treated subsequently only by conventional ADT, 17 tumours (65%) showed a low PCD index and nine carcinomas (35%) exhibited a high PCD index. The PCD index correlated statistically significantly with tumour grade (P < 0.05, Spearman correlation) and, as mentioned above, with Ki-67 index (P < 0.05, Spearman correlation). Moreover, a positive correlation between PCD index and patients, age could be found (P < 0.02). In nearly all cases, scarce apoptotic cells were also detected by terminal transferase reaction in the secretory epithelial cells of non-neoplastic prostatic glands.
Prognostic significance
The only parameter with statistically significant prognostic impact on prognosis before ADT was the p21/WAF1 expression of the tumour cells. Patients with p21/WAF1-positive carcinomas showed a statistically significant shorter survival time than those with p21/WAF1-negative tumours (P < 0.0002, log-rank test, in all untreated prostatic carcinomas, Figure 3A ; P < 0.00001, log-rank test, in the 'core-group' treated only with conventional ADT, Figure 3B ).
Prostatic carcinomas after ADT
Histologic grade and signs of tumour regression
In the cases where paired tumour samples before and after ADT were available, the Gleason score increased significantly after therapy (P < 0.001, Wilcoxon's signed rank test).
From the total of 69 PC after ADT, 24 carcinomas (35%) showed histologic signs of tumour regression. In the subgroup treated only with conventional ADT, 18 of 40 cases (45%) demonstrated histologic changes that could be related to the therapy. Independently, whether only a conventional ADT or an additional radiation or chemotherapy had been performed, in all of these cases, the histologic signs of regression were only slight and could be observed only in a part of the tumour tissue.
AR molecule
After ADT, 61 PC (88%) expressed the AR molecule. After pretreatment with conventional ADT only, 36 of 40 carcinomas (90%) were AR-positive, including all of the 26 cases in which also paired tumour tissue before ADT had also been analysed. The remaining cases showed no immunoreactivity or a positive reaction only in a few cells (< 5%). The loss of the AR molecule was associated with high-rate p21/WAF1 (P < 0.02, Fisher's exact test) and high-rate bcl-2 (P < 0.04, Fisher's exact test) and with a tendency to high Ki-67 index.
bcl-2
In 42 of the carcinomas after ADT (61%), a positive cytoplasmatic immunoreactivity for bcl-2 could be found. After conventional ADT, 58% of the tumours showed bcl-2 positivity. Thus, a trend towards a higher rate of bcl-2 expression after ADT could be registered.
p53
In 26 PC (38%), a nuclear p53 accumulation could be observed. In the ADT subgroup without additional therapeutic regimens, 12 of 40 tumours (30%) reacted p53 positively; in the 26 core-group cases with paired tumour samples this rate was 39%. In comparison with the results before ADT the rate of aberrant immunohistochemical p53 expression increased insignificantly. After ADT, p53 accumulation and p21/WAF1 expression were correlated statistically significantly (P < 0.0001, Pearson χ 2 test). p21/WAF1 Thirty-one PC analysed after ADT (45%) showed a positive nuclear reaction for p21/WAF1 ( Figure 4A ). The distribution of cases with focal and high-rate p21/WAF1 immunoreactivity is shown in Table 4 . In comparison to the status before ADT, the rate of p21/WAF1 overexpression increased significantly (P < 0.004, McNemar test). In the paired tumour samples after conventional ADT only, 12 of 26 prostatic carcinomas reacted p21/WAF1 positively (46%; P < 0.02, McNemar test). As mentioned above, p21/WAF1 expression correlated with p53 accumulation (P < 0.0001, Pearson χ 2 test), as well as with Ki-67 index (P < 0.01, Pearson χ 2 test; Figure 4B ).
Ki-67
After ADT, the mean value of the Ki-67 index was 26.3 ± 18.5% in the PC. The Ki-67 index was classified as low in 25 cases (36%), and as high in 44 cases (64%). In the 40 patients treated only with conventional ADT, these rates were 38% and 62% respectively. In the 'core-group', the distribution of tumours was 46% low and 54% high Ki-67 index. A significant increase towards higher Ki-67 index was shown in paired sample analysis (P < 0.01, Wilcoxon's signed rank test). The Ki-67 index was statistically significantly correlated with grading (P < 0.001, Spearman correlation) and PCD rate (P < 0.05, Spearman correlation). Furthermore, in tumours with histologic signs of regression, the rate of cases with low Ki-67 index was statistically significantly higher (67%) than in the carcinomas without tumour regression (14%; P < 0.01, Pearson χ 2 test).
Apoptosis
The mean value of the PCD index in the 69 prostate carcinomas after ADT was 3.8 ± 3.6%. According to the limits mentioned above, the PCD index was classified as low in 35 cases (51%) and high in 34 cases (49%). In the subgroup treated only with conventional ADT, the cases with low and high PCD index were distributed into 60% low and 40% high PCD index. Thus, in comparison with the status before ADT, a slight decrease of cases with high PCD index could be found. PCD index correlated with grading (P < 0.002, Spearman correlation) and with Ki-67 index (P < 0.05, Spearman correlation).
Prognostic significance
In the total of 66 patients with all forms of treatment and clinical follow-up data available, patients whose tumours showed highrate p21/WAF1 had a significantly shorter survival time than the others (P < 0.006, log-rank test; Figure 5A ). This result became even more evident in the subgroup treated by conventional ADT only (n = 40; P < 0.00001, log-rank test; Figure 5B ). Moreover, in the 'core-group' pretreated with conventional ADT only, the Ki-67 index and the PCD rate were statistically significant prognostic parameters as well (Table 5) .
DISCUSSION
The molecular mechanisms underlying androgen-independent growth in PC after long standing ADT are still poorly understood. Elucidation of these processes might lead to improvement of existing endocrine therapeutic regimens or to the development of new forms of therapy (Trapman and Brinkmann, 1996) . In the present investigation, we analysed immunohistochemically several factors known to be involved in the regulation of proliferation and PCD/apoptosis. By comparing the results from both the primary untreated PC and the recurrences after a longer period of ADT from the same patients, we hoped to gain a better understanding of these pathways in PC tumour cells. Since in several cases other therapy regimens were performed in addition to conventional ADT, the collective was subclassified into groups with either conventional ADT alone or with ADT and additional chemotherapy or radiation to avoid therapy-related influences on the results. On the one hand, the discrepancies between these groups observed in our study concerning the correlations and/or the prognostic impact of the analysed parameters support the necessity of a stratification of the patients with advanced prostate cancer according to the applied therapy regimen (Table 5 ). On the Table 5 Expression patterns of proliferation-/apoptosis-regulating factors, proliferative activity (Ki-67 index), and apoptosis/PCD rate in advanced prostatic carcinomas before and after ADT and prognostic significance Expression patterns of proliferation-/apoptosis-regulating factors, proliferative activity (Ki-67 index), and apoptosis/PCD rate in advanced prostatic carcinomas before and after ADT and prognostic (progn. significance (sign.) of the parameters (log-rank test). Left: Cases with paired specimens from both the untreated primary tumour and the recurrence after conventional ADT only; a statistically significant increase after ADT (P < 0.02, McNemar test). Right: All cases under study before and after ADT with and without additional chemotherapy or radiation; b high rate p21/WAF1-overexpression only.
other hand, these findings may explain differences between the results of our study and other investigations published in the literature, where no stratification was performed.
In accordance with the majority of reports in the literature, the immunohistological AR expression was preserved in all tumours of our series before ADT and did not correlate with clinical and histopathologic features (Trapman and Brinkmann, 1996) . After ADT, loss of the AR molecule could be found in less than 10% of cases. The observed association between AR loss and high Ki-67 index suggests that the AR-regulated growth control is overruled in this subset of cases by other factors, e.g. activation of 'classical' oncogenes and/or inactivation of tumour suppressor genes. This hypothesis is further supported by the observation that the Ki-67 index (and the PCD rate) were prognostically relevant for survival in the subgroup after conventional ADT.
Furthermore, our data show that the physiologic regulation of cell proliferation and apoptosis are obviously defective already before ADT in the majority of advanced PC. Before and after ADT the PCD rate was associated only with tumour grade and proliferative activity assessed by the Ki-67 index. No correlation could be observed between PCD rate and the PCD-inhibiting bcl-2 oncoprotein expression (Korsmeyer, 1992b) , supporting the view that regulation of apoptosis is complex and bcl-2 is not the only factor involved in this process (Krajewska et al, 1996) . For example, apoptosis may also be initiated by incompatible or conflicting growth signals (Stewart, 1994) , e.g. by c-myc, or by the activation of a cyclin-dependent kinase at an inappropriate time during the cell cycle (Evan et al, 1992) . In agreement with earlier reports, the rate of tumours expressing bcl-2 was higher after ADT (McDonnell et al, 1992; Colombel et al, 1993; Westin et al, 1995) , although the increase was not statistically significant in our cases. In contrast to other studies, no correlations between bcl-2 overexpression and PCD rate, p53 accumulation, or clinical outcome could be observed before and after ADT. In these investigations, however, either locally confined, i.e. resectable prostatic carcinomas (Bubendorf et al, 1996) , or short-term changes after ADT were studied (McDonnell et al, 1992; Westin et al, 1995) .
The TP53 tumour suppressor gene is the most commonly mutated gene in human cancers (Levine et al, 1991) . The p53 protein plays a central role in the regulation of proliferation and PCD. Its main physiologic function is controlling the integrity of the DNA (Lane, 1992) . If DNA damage is present the cell cycle will be stopped in the G1 phase mediated by the p53 effector protein p21/WAF1, and DNA repair is induced. If the damage is irreparable, apoptotic cell death is induced. Thus, inactivation of p53 is able to block apoptotic cell death (Korsmeyer, 1992a) . As functionally relevant mutations of the TP53 gene mostly result in an abnormal stabilization of the mutated protein, its accumulation can be visualized by immunohistochemistry, whereas the wildtype p53 escapes detection due to the short half-life time. In PC, p53 immunohistology was proven to correlate well with TP53 gene mutations (Wertz et al, 1996) . Nonetheless, TP53 mutations seem to be a late event in PC progression and are identified mainly in poorly differentiated and metastatic tumours, indicating an association with poor prognosis (Visakorpi et al, 1992; Bookstein et al, 1993; Navone et al, 1993; Eastham et al, 1995; Kubota et al, 1995; Shurbaji et al, 1995) The rates of approximately 30% and 40% of p53 positivity in advanced PC before and after ADT, respectively, are within the range of results for abnormal p53 accumulation published in the literature. In our series, however, no statistically significant correlations between p53 accumulation and clinicopathological features or prognosis could be established.
Obviously, the main result of our study was that overexpression of the p21/WAF1 protein, the effector of the wild-type p53 protein, was statistically significantly correlated with a shorter survival time of the patients (Figures 3 and 5) . As p21/WAF1 is physiologically a potent inhibitor of cyclin-dependent kinases (CDK) and can be regarded as a negative regulator of the cell cycle inducing either p53-mediated G1 arrest or apoptosis, this finding was unexpected (El-Deiry et al, 1994; Li et al, 1994; Polyak et al, 1997) . Accordingly, loss of p21/WAF1 expression was described mainly in more aggressive tumour variants or advanced tumour stage (Ellis et al, 1997; Gomyo et al, 1997; Harada et al, 1997; Maelandsmo et al, 1997; Wang et al, 1997) .
However, no statistically significant correlation could be found between p53 accumulation and p21/WAF1 expression before ADT in our study. This is in agreement with the observation that p21/WAF1 can be activated by a p53-independent pathway as well (Michieli et al, 1994) . After ADT, the rate of both p53 accumulation and p21/WAF1 overexpression increased and a statistically significant positive correlation between both factors could be observed. This finding might be explained by a potentially therapy-related up-regulation of functional (wild-type) p53 protein.
Paradoxically, all p21/WAF1-positive cases in our series showed a high Ki-67 index and, occasionally, mitoses were also p21/WAF1 immunoreactive (Figure 4) . Our results are in accordance with recent data from Trotter et al (1997) and from Erber et al (1998) who were able to show an aberrant p21/WAF1 expression in human cutaneous melanomas and head and-neck squamous cell carcinomas respectively. These data demonstrate that increased p21 expression is not sufficient to control growth of certain tumour entities in vivo. Moreover, Lukas et al (1997) revealed tissue-specific expression patterns of p21/WAF1 in carcinomas of the breast, ovary and endometrium which appeared to be characteristic of the tumour type. This finding suggests an abnormal function of this important cell cycle inhibitor in a subset of the tumour cells, resulting in a defective G1/S checkpoint control and leading to an excessive tumour cell proliferation in some human malignancies. Several molecular changes might cause this escape from the regular cell cycle control, including (1) mutations of the p21/WAF1 gene, (2) an alteration 'downstream' from the p53 and p21/WAF1-mediated G1/S checkpoint, or (3) changes in other factors participating in the G1/S checkpoint control (checkpoint adaptation, mutations of the CDKs or their inhibitors).
To date, direct evidence for one of these hypotheses is lacking. Nonetheless, PC was the first primary human cancer where somatic mutations of the WAF1/CIP1 gene were detected. The question of whether the mutated p21 protein is functional or nonfunctional is still open. The rate of 17% of WAF1 gene mutations in prostatic carcinomas reported by Gao et al (1995) is very similar to the frequency of immunohistochemical p21/WAF1 protein overexpression detected before ADT in the present study. Thus, it might be speculated that WAF1 gene mutations could lead to a mutated protein with abnormal stability. The abnormal proteineither functional or non-functional -might become detectable by immunohistochemistry in analogy to p53. Alternatively, the binding of p21/WAF1 to the cyclin/CDK complexes might be altered or inhibited by gene mutations. However, no data are as yet available concerning the correlation between WAF1 gene mutations and p21/WAF1 protein overexpression. Recently, Blagosklonny et al (1997) were able to show that the prostate cancer cell line, LNCaP, became resistant to phorbol-12-myristate-13-acetate (PMA)-induced growth arrest after transfection with the c-myc oncogene, despite up-regulation of p21/WAF1. Thus, continued c-myc expression obviously provided a circumvention of growth inhibition by tumour suppressors. Furthermore, upregulation of cyclins might also bypass the p21-inhibitory effect by altering binding stoichiometry (Trotter et al, 1997 ) and p53-induced p21 WAF1 expression can mediate increased cyclin D1 synthesis itself .
In conclusion, our results show that the physiologic regulation of proliferation and apoptosis is defective in the majority of advanced prostatic carcinomas already before ADT. The aberrant expression of the cell cycle inhibitor p21/WAF1 in the tumour cells before androgen withdrawal characterized a subgroup of patients with unfavourable clinical course. This finding indicates that the physiologic G1/S checkpoint of the cell cycle might be impaired in these tumours. Further investigations will be necessary to elucidate the causes for this failure on DNA and RNA level. For the clinical practice, prospective investigations will have to clarify whether the immunohistochemical demonstration of p21/WAF1 overexpression in advanced prostate carcinomas can be used as a marker for hormone-refractory high-risk tumours. According to our results, these patients have no benefit from conventional androgen deprivation therapy forms.
